Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 9/20 | 0.57 |
| ▸ | PARP1 | P09874 | 4/20 | 0.51 |
| ▸ | HTR3A | P46098 | 1/20 | 0.43 |
| ▸ | APAF1 | O14727 | 1/20 | 0.41 |
| ▸ | CDC25B | P30305 | 1/20 | 0.41 |
| ▸ | CASP3 | P42574 | 1/20 | 0.41 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.41 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.40 |
| ▸ | KIF11 | P52732 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6649511 | 0.95 | TNKS (0.61) | TNKSPARP1HTR3AAPAF1CDC25B | |
| SCHEMBL6649536 | 0.86 | TNKS (0.56) | TNKSPARP1HTR3A | |
| SCHEMBL6644553 | 0.83 | TNKS (0.48) | TNKSPARP1APAF1CDC25BCASP3 | |
| SCHEMBL6648492 | 0.82 | TNKS (0.49) | TNKSPARP1APAF1CDC25BCASP3 | |
| SCHEMBL6648820 | 0.82 | APAF1 (0.63) | TNKSPARP1HTR3AAPAF1CDC25B | |
| SCHEMBL6650173 | 0.81 | PARP1 (0.47) | TNKSPARP1POLBL3MBTL1 | |
| SCHEMBL6649526 | 0.81 | TNKS (0.47) | TNKSPARP1POLBL3MBTL1 | |
| SCHEMBL6649242 | 0.81 | TNKS (0.46) | TNKSPARP1APAF1CDC25BCASP3 | |
| SCHEMBL6644897 | 0.80 | APAF1 (0.64) | TNKSPARP1APAF1CDC25BCASP3 | |
| SCHEMBL6646262 | 0.80 | HTR3A (0.46) | TNKSPARP1HTR3AAPAF1CDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | claimed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | claimed |
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | MITSUBISHI PHARMA CORPORATION (JP) | 2004-09-09 | — | — | US | disclosed |
| EP-1396488-A1 | FUSED HETEROCYCLIC COMPOUND AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176361-A1 | Fused heterocyclic compound and medicinal use thereof | PARP11, PARP1, CD38 | TNKS 121/4885PARP1 2/4885HTR3A 2987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.